ABIO : Summary for ARCA biopharma, Inc. - Yahoo Finance

U.S. Markets closed

ARCA biopharma, Inc. (ABIO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.60+0.05 (+1.96%)
At close: 4:00PM EST
People also watch
AEZSACURCYCCAPPYOPXA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.55
Open2.50
Bid0.00 x
Ask0.00 x
Day's Range2.50 - 2.60
52 Week Range2.15 - 4.35
Volume4,607
Avg. Volume31,593
Market Cap23.61M
Beta0.98
PE Ratio (TTM)-1.53
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Anders Hove, MD Joins ARCA biopharma Board of Directors
    Business Wire5 days ago

    Anders Hove, MD Joins ARCA biopharma Board of Directors

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Anders Hove, M.D., has joined its Board of Directors.

  • ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial
    Business Wirelast month

    ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 150th patient has been randomized into GENETIC-AF, a seamless Phase 2B/3 clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation .

  • Business Wire2 months ago

    ARCA biopharma to Present at Biotech Showcase 2017

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a corporate overview at the Biotech Showcase 2017, taking place January 9-11, 2017 in San Francisco, California.